Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab
Sign Up to like & getrecommendations! Published in 2018 at "Pediatric Nephrology"
DOI: 10.1007/s00467-018-4033-0
Abstract: BackgroundThis study aims to identify epidemiological and clinical characteristics of patients and report our experience with eculizumab treatment during an outbreak of hemolytic uremic syndrome (HUS) caused by Shiga toxin-producing Escherichia coli (STEC) in Istanbul… read more here.
Keywords: uremic syndrome; toxin producing; hemolytic uremic; experience eculizumab ... See more keywords
Ten Years of Clinical Experience With Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria.
Sign Up to like & getrecommendations! Published in 2018 at "Seminars in Hematology"
DOI: 10.1053/j.seminhematol.2018.04.001
Abstract: Abstract Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation in the phosphatidylinositol glycan class A, X-linked gene, responsible for a deficiency in glycosyl phosphatidylinositol-anchored proteins. The absence of one of the glycosyl phosphatidylinositol-anchored protein… read more here.
Keywords: years clinical; paroxysmal nocturnal; eculizumab; experience eculizumab ... See more keywords